Difference between revisions of "Lobaplatin (D-19466)"
Jump to navigation
Jump to search
m |
m |
||
| Line 16: | Line 16: | ||
[[Category:Platinum agents]] | [[Category:Platinum agents]] | ||
[[Category:Alkylating agents]] | [[Category:Alkylating agents]] | ||
| + | |||
| + | [[Category:Nasopharyngeal carcinoma medications]] | ||
| + | |||
[[Category:NMPA approved in 2005]] | [[Category:NMPA approved in 2005]] | ||
Revision as of 23:39, 6 November 2023
General information
Class/mechanism: Third-generation platinum compound with DNA alkylating activity, producing interstrand DNA crosslinks, which result in apoptosis.[1]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Also known as
- Code name: D-19466